阴道孕酮预防单胎妊娠短宫颈早产及不良围产结局:个体患者数据荟萃分析
该系统评价与个体患者数据荟萃分析纳入5项高质量随机对照试验的974例单胎妊娠且孕中期超声宫颈长度≤25 mm的无症状孕妇,比较阴道孕酮与安慰剂/无治疗。阴道孕酮显著降低<33周早产风险(RR 0.62,95%CI 0.47-0.81,P=.0006,高质量证据),并改善多项围产结局,对2岁神经发育无不良影响。
要点
- 阴道孕酮降低<33周早产风险(RR 0.62,95%CI 0.47-0.81,P=.0006,高质量证据)。
- 阴道孕酮显著降低<36至<28周早产、呼吸窘迫综合征、复合新生儿疾病与死亡、低出生体重及新生儿重症监护病房入院风险(RR 0.47-0.82,均为高质量证据)。
- 新生儿死亡两组无显著差异(孕酮组1.4% vs 安慰剂组3.2%,RR 0.44,95%CI 0.18-1.07,P=.07,低质量证据)。
核心结论
- 阴道孕酮可降低孕中期超声短宫颈单胎妊娠的早产风险并改善围产结局,且未显示对儿童神经发育有不良影响。
研究设计与样本
- 系统评价与个体患者数据荟萃分析,检索MEDLINE、EMBASE、LILACS、CINAHL(自建库至2017年9月)、Cochrane数据库、参考文献及会议论文集。
- 纳入比较阴道孕酮与安慰剂/无治疗的随机对照试验,对象为单胎妊娠且孕中期超声宫颈长度≤25 mm的无症状孕妇。
- 共5项高质量试验、974例孕妇(阴道孕酮组498例,安慰剂组476例),采用两阶段法分析个体患者数据, GRADE方法评估证据质量。
主要发现
- 阴道孕酮组<33周早产风险显著低于安慰剂组(RR 0.62,95%CI 0.47-0.81,P=.0006,高质量证据)。
- 阴道孕酮显著降低<36、<35、<34、<32、<30、<28周早产风险,以及<33和<34周自发性早产、呼吸窘迫综合征、复合新生儿疾病与死亡、出生体重<1500 g和<2500 g、新生儿重症监护病房入院风险(RR 0.47-0.82,均为高质量证据)。
- 新生儿死亡孕酮组7例(1.4%) vs 安慰剂组15例(3.2%)(RR 0.44,95%CI 0.18-1.07,P=.07,低质量证据),两组无显著差异。
- 母亲不良事件、先天畸形及2岁时不良神经发育和健康结局两组无差异。
关键数值与推荐
- 宫颈长度≤25 mm的无症状单胎妊娠孕妇,阴道孕酮较安慰剂/无治疗降低<33周早产风险(RR 0.62,95%CI 0.47-0.81,P=.0006,高质量证据)。
- 新生儿死亡孕酮组1.4% vs 安慰剂组3.2%(RR 0.44,95%CI 0.18-1.07,P=.07,低质量证据),无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix has been questioned after publication of the OPPTIMUM study. OBJECTIVE: To determine whether vaginal progesterone prevents preterm birth and improves perinatal outcomes in asymptomatic women with a singleton gestation and a midtrimester sonographic short cervix. STUDY DESIGN: We searched MEDLINE, EMBASE, LILACS, and CINAHL (from their inception to September 2017); Cochrane databases; bibliographies; and conference proceedings for randomized controlled trials comparing vaginal progesterone vs placebo/no treatment in women with a singleton gestation and a midtrimester sonographic cervical length ≤25 mm. This was a systematic review and meta-analysis of individual patient data. The primary outcome was preterm birth <33 weeks of gestation. Secondary outcomes included adverse perinatal outcomes and neurodevelopmental and health outcomes at 2 years of age. Individual patient data were analyzed using a 2-stage approach. Pooled relative risks with 95% confidence intervals were calculated. Quality of evidence was assessed using the GRADE methodology. RESULTS: Data were available from 974 women (498 allocated to vaginal progesterone, 476 allocated to placebo) with a cervical length ≤25 mm participating in 5 high-quality trials. Vaginal progesterone was associated with a significant reduction in the risk of preterm birth <33 weeks of gestation (relative risk, 0.62; 95% confidence interval, 0.47-0.81; P = .0006; high-quality evidence). Moreover, vaginal progesterone significantly decreased the risk of preterm birth <36, <35, <34, <32, <30, and <28 weeks of gestation; spontaneous preterm birth <33 and <34 weeks of gestation; respiratory distress syndrome; composite neonatal morbidity and mortality; birthweight <1500 and <2500 g; and admission to the neonatal intensive care unit (relative risks from 0.47-0.82; high-quality evidence for all). There were 7 (1.4%) neonatal deaths in the vaginal progesterone group and 15 (3.2%) in the placebo group (relative risk, 0.44; 95% confidence interval, 0.18-1.07; P = .07; low-quality evidence). Maternal adverse events, congenital anomalies, and adverse neurodevelopmental and health outcomes at 2 years of age did not differ between groups. CONCLUSION: Vaginal progesterone decreases the risk of preterm birth and improves perinatal outcomes in singleton gestations with a midtrimester sonographic short cervix, without any demonstrable deleterious effects on childhood neurodevelopment.
引用
- Romero R, Conde-Agudelo A, Da Fonseca E, et al. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data. Am J Obstet Gynecol. 2017. PMID: 29157866. doi:10.1016/j.ajog.2017.11.576
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。